AT1 RECEPTOR CONTROL IN CHRONIC HYPERTENSION ATTENUATION
Project Number5R01HL056921-06
Contact PI/Project LeaderRAIZADA, MOHAN K.
Awardee OrganizationUNIVERSITY OF FLORIDA
Description
Abstract Text
DESCRIPTION (Adapted from Applicant's Abstract): Hypertension is a complex
pathological state that is manifested as chronic blood pressure. It affects all
vital organs, and is a major risk for many cardiovascular diseases.
Overwhelming evidence has established that an altered renin-angiotensin system
(RAS) plays a key role in the development and establishment of hypertension.
Thus, traditional pharmacological agents that influence the RAS are effective
antihypertensive therapy. In spite of its success, the traditional therapy is
not a cure of hypertension and suffers from many side effects and compliance
issues. As a result, the investigators set out to investigate the possibility
of genetic targeting of the RAS as a means to control hypertension on a
long-term basis. Their studies have established that a single dose of a
retroviral vector containing angiotensin II type I receptors antisense
(AT1R-AS) or angiotensin-converting enzyme antisense (ACE-AS) prevents
hypertension for life in the spontaneously hypertensive rat (SHR). These
observations led them to conclude that the antisense therapy (AS) is
conceptually sound, technically feasible, and may hold promise for cure of
hypertension. The objective during this grant period is to test an overall
hypothesis that AS targeting to regulate the expression of the RAS would
prevent the development of hypertension on a permanent basis as a result of
genomic integration of AT1R-AS or ACE-AS. If successful, a regulatable system
of the AS, and thus antihypertensive actions, could be controlled on demand.
The aims of the study are: 1) investigate the mechanism of a long-term
protection against hypertension by the AT1R-AS gene therapy; 2) investigate
involvement of central angiotensin in antihypertensive actions of AT1R-AS gene
therapy; 3) investigate the role of tissue RAS in hypertension, and 4)
establish long-term reversal of hypertension by the use of a novel viral vector
system. State-of-the-art techniques of gene transfer, viral vectors, and
molecular biology will be used to accomplish these aims. The investigators
believe that this research proposal is low risk in nature and will have high
impact in the development of strategies for long-term control of hypertension.
The outcome of this research has a potential to be immediately adapted for the
treatment of human hypertension and other cardiovascular diseases.
No Sub Projects information available for 5R01HL056921-06
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HL056921-06
Patents
No Patents information available for 5R01HL056921-06
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HL056921-06
Clinical Studies
No Clinical Studies information available for 5R01HL056921-06
News and More
Related News Releases
No news release information available for 5R01HL056921-06
History
No Historical information available for 5R01HL056921-06
Similar Projects
No Similar Projects information available for 5R01HL056921-06